RICHMOND HILL, ON / ACCESSWIRE / August 31, 2020 – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immunooncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020 to divest the remaining shares it holds in its Polish subsidiary (the “Divestment”), Helix Immuno-Oncology S.A. (“HIO”).
20200831 – HBP Press Release – Polish Subsidiary Divestitutre Update